The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Graham Duncan from sunday roast
Ahahahahaha
Muppets always sell they dont know how to invest
Muppets always sell first and then ask questions later
Oh dear the muppets all panic selling
Duh
Yes normal rule breaking BS,having said that Chill will probably head back to 20p plus as there is massive demand for Vapes its unstoppable
With the Neuralink connection and other recent contract wins,don't rule out other private equity players circling the wagon.
No reason to think Roxi should get something for basically nothing
10p should be the floor as they claim they want "an ordely exit" for shareholders
Absolute steal at these levels
Revenues will soar over 500% in next 2 years according to Liberum
They will book $4 million upfront this year plus possibly another $5 million is as is likely Halen launch into the usa this year
Patent protection already to 2040 in UKEU plus likely to be granted in the USA and ROW this year
Stifel continued
"Importantly, Futura is fully funded through to profitability, supported by UK and European revenues, with US royalty revenues expected in FY25.
"We note that profitability might come sooner than our current expectations if there is an earlier-than-anticipated US launch in FY24, triggering an estimated $5m launch milestone in the process."
Clinically proven, topical gel treatment for erectile dysfunction, Eroxon, offers a "significant and still underappreciated opportunity", said Stifel as it initiated coverage on the stock with a 'buy' rating.
As highlighted in today's results, Eroxon last year received marketing approval in the US, EU and UK and is in the early stages of the commercial launch in the UK and EU with its US launch on the horizon, under a partnership with Advil and Sensodyne maker Haleon.
The shares offer "a compelling investment opportunity" as the US launch approaches, said the brokerage, setting a 125p share price target.
The initiation note also highlighted the ED market is large at $3.5 billion annually and still growing, with Eroxon's key differentiating features versus current treatments being rapid onset of action, cleaner safety profile and unique off-the-shelf status.
Eroxon is a "true off-the-shelf product, available without prescription or consultation" and its drug free profile "means there are no restrictions on use or contraindications with other drugs, making it a treatment for nearly all ED sufferers", analysts said.
As a topical application with an onset of action under 10 minutes reduces side effects and increase spontaneity, "addressing two key limitations associated with current treatment options".
Future generated first revenue last year of £3.1 million and Stifel forecasts this rising to £9.2 million this year and £15.8 million in 2025, when it forecasts a first pre-tax profit.
House broker Liberum's estimates are for £10 million sales this year and £18 million in 2025.
Stifel forecasts peak worldwide sales of $364 million for Eroxon in 2029, though a chunk of that will be absorbed by distributors and other middlemen.
The majority of expected sales are seen derived from the US market, around $223 million (£176m) in that year, with Europe peaking at $117 million by 2028.
Most amusing to watch the trolls busy in action
You really do not need much of a brain to work out that a co that has reached cash flow breakeven is worth significantly more that when it hasnt.
But I blame it on the government that educates most of the population.
Think British Leyland cars in peoples brains
Clearly you have no idea about this co.If you did you would know exactly what I am talking about.
Furthermore the co received bid approaches close to 300p a year ago
The fact that the co has made significant progress since that time only adds to its true value
Are you paid per post to troll?
Now the normal results day trading is done,back to the fundamentals.
The sum of the parts valuation is around 240p a share
Current share price 60p a share
Talk about a huge margin of safety,some 300% upside